GC Genome said Monday that it has submitted a preliminary listing application for the Kosdaq market with the Korea Exchange, following its successful technical evaluation.

The company received “A, A” grades from two agencies authorized by the Korea Exchange—the Korea Technology Finance Corporation and the Korea Technology Credit Bureau—based on criteria such as technology, business viability, and growth potential. Samsung Securities is acting as the underwriter for the initial public offering (IPO).

The company plans to complete the IPO in the first half of 2025 under the technology-growth special listing track. It aims to leverage its expertise in genetic analysis and AI-driven precision diagnostic solutions to support its growth strategy.

GC Genome, a Korean clinical genome testing company founded in 2013 as an affiliate of GC Group, specializes in disease diagnosis, risk prediction, and personalized treatment solutions. The company reported revenue of 27.3 billion won ($19.5 million) in 2023, achieving an average annual growth rate exceeding 20 percent over the past five years.

The company holds a major domestic market share for non-invasive prenatal testing (NIPT), obstetric diagnostics, cancer detection, and rare disease genetic testing. 

Additionally, GC Genome provides over 300 molecular diagnostic services across obstetrics, health screening, cancer, and rare disease testing to approximately 900 hospitals and clinics in Korea. Its services also reach 19 countries, including the U.S., Europe, the Middle East, and the Asia-Pacific region.

In October last year, GC Genome launched its AI-powered liquid biopsy technology for early cancer detection in Korea. The platform, called ai-CANCERCH (ai-CANCER Search), detects six major cancers—lung, liver, colorectal, pancreatic/biliary, esophageal, and ovarian—through a single blood sample. Clinical trials involving over 7,000 samples, conducted in partnership with leading university hospitals, demonstrated 82.2 percent sensitivity, showcasing the platform’s potential for early cancer detection.

GC Genome also became the first Korean liquid biopsy company to license its technology to a U.S.-based firm, signing an exclusive deal with Genece Health for early cancer detection.

The company said it plans to use proceeds from its IPO to enhance and globalize its ai-CANCERCH platform, accelerate market expansion, and invest in advanced R&D for diagnostic solutions.

“Passing the technical evaluation validates both our technology and market potential,” said GC Genome CEO Ki Chang-seok. “The Kosdaq listing will be a pivotal milestone, enabling us to broaden our investment base and redefine global cancer diagnostics.”